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Summary 
Numerous experimental models have demonstrated that graft-vs.-host disease (GVHD) does not 
occur in irradiation chimeras when the graft does not contain mature, immunocompetent T 
lymphocytes, but clinical studies have shown that T cell depletion of donor marrow can be associated 
with a greatly increased risk of graft failure. We have developed a model where engraftment 
of  (C57BL/6J  x  C3H/HeJ)F1  (B6C3)  marrow  in  800-cGy-irradiated  (BALB/cJ  x 
C57BL/6J)F1  (CB6) recipients depends on the presence of donor T cells in the graft. Recipients 
transplanted with 5.0  x  106 marrow cells depleted of T  lymphocytes showed host lymphoid 
and myeloid reconstitution, whereas recipients transplanted with the same marrow plus 2.5  x 
105 purified donor T  cells showed donor reconstitution. Adding as few as 0.5  x  10  s CD8- 
enriched donor T cells to marrow grafts containing 5.0  x  106 T cell-depleted donor cells was 
sufficient to enable donor reconstitution, while surviving recipients transplanted with the same 
marrow and 0.5-2.5  x  10  s CD4-enriched donor cells showed only host reconstitution. To 
address the question of whether donor CD4 cells could facilitate engraftment under conditions 
where GVHD would not represent a limiting factor, engraftment of bin1 marrow was tested 
in  major  histocompatibility complex (MHC)  class I-disparate  B6.Ly5  ~ recipients.  Results 
indicated that the donor CD8-enriched population was at least fivefold more active than the 
CD4-enriched population for facilitating allogeneic marrow engraftment in this strain combination. 
Thus, the lymphokines and MHC class II-specific cytotoxic T cells generated by CD4 cells were 
relatively ineffective for enhancing engraftment, possibly reflecting the fact that the host T cells 
that contain effectors responsible for causing rejection do not express MHC class II antigens. 
The ability of donor CD8 cells to facilitate engraftment could reflect the activity of a cytokine 
uniquely elaborated after recognition of an MHC dass I disparity. More likely, the graft-enhancing 
effect of donor CD8 cells may result from the generation of MHC class I-specific or class I-restricted 
cytotoxic T cells that recognize the host CD4 and CD8 cells responsible for causing rejection. 
The possibility remains that other mechanisms such as veto inactivation of host T cells by donor 
CD8 cells may also contribute to the graft-enhancing effect. 
N 
'umerous experimental models have demonstrated that 
GVHD does not occur in irradiation chimeras when 
the graft does not contain mature, immunocompetent  T lym- 
phocytes  (reviewed  in  reference  1).  These  observations 
prompted wide-spread clinical trials testing whether removal 
of T  cells from donor marrow could prevent GVHD  in 
humans. Results from these studies have confirmed the ex- 
pectation that T cell depletion can decrease the incidence and 
severity of GVHD (reviewed in reference 2). Although there 
was little evidence from animal experiments that T cell deple- 
tion could lead to complications, clinical studies demonstrated 
that this approach for preventing GVHD can be associated 
with a greatly increased risk of graft failure (reviewed in ref- 
erence 2). Thus, with unmodified HLA-identical marrow, 
the risk of graft failure is <2%, but with T cell depletion, 
the risk increases to 10-25%. Graft failure after human marrow 
transplantation usually leads to a fatal outcome because spon- 
taneous reconstitution with host cells seldom occurs and be- 
cause patients generally cannot tolerate the preparative regimen 
for another transplant (3,  4). 
Precise causes for graft failure associated with T cell deple- 
tion of donor marrow in humans remain difficult to define. 
Deficiency of T cell-derived lymphokines required for prolifer- 
ation and differentiation of hematopoietic cells and absence 
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represent two possible explanations that are not mutually ex- 
clusive. Small numbers of host lymphoid cells are known to 
survive the chemotherapy and total body irradiation (TBI) 1 
regimens used for human marrow transplantation (5). Thus, 
donor T  cells may help to eliminate or inactivate these re- 
sidual host  cells  that  would otherwise remain capable of 
causing rejection. In support of this hypothesis are observa- 
tions that depletion of donor T cells is associated with a high 
incidence  of mixed  lymphoid  and  mixed  hematopoietic 
chimerism (i.e.,  persistence of host cells) after transplanta- 
tion (3,  6-10),  Moreover, host CD8-positive T  cells with 
specific antidonor cytotoxic or suppressive activity have been 
identified in the blood of patients with graft failure after T 
cell-depleted marrow transplantation (11-17).  Finally,  sev- 
eral studies of T cell-depleted marrow transplantation have 
shown an inverse relationship between the risk of graft failure 
and the intensity of the conditioning regimen, implicating 
an active role for host cells in causing graft failure (3, 18-20). 
In the present study, we sought to develop an experimental 
model that would enable an exploration of the role played 
by donor T  cells in facilitating allogeneic marrow engraft- 
ment. Thus, it was necessary to determine conditions in which 
engraftment depends on the presence of donor T cells. Having 
done so, we then carried out experiments to determine the 
phenotype of the cells responsible for this effect and to assess 
the mechanisms possibly involved. The results suggest that 
donor T cells enhance engraftment through mechanisms that 
depend on interactions with host T  cells. 
Materiah and Methods 
Mice.  (C57BL/6J  x  C3H/I-hJ)F1  (B6C3; H-2  b/k) males, 
(BALB/cJ  x  C57BL/6J)FI (CB6; H-2  a;~ females, and B6.C-H- 
2  bml (bin1) males were purchased from The Jackson Laboratory 
(Bar Harbor, ME). B6.Ly-5.1:pep3  b (B6-LyS') females were bred 
at the Fred Hutchinson Cancer Research Center. Founder B6.Ly- 
5  ~ males and females were kindly provided by Dr. David Myers 
(Sloan Kettering Institute, New York, NY). Mice were housed in 
groups of five under microisolated, specific pathogen-free condi- 
tions with twice weekly cage changes and were given sterilized 
chow and acidified  water (pH 3.5) ad libitum. 4 wk after marrow 
transplantation, mice were transferred to conventional  housing con- 
ditions. Experiments were reviewed and approved by the Institu- 
tional Animal Care and Use Committee of the Fred Hutchinson 
Cancer Research Center. 
Marrow Transplantation.  Recipients 7-8 wk of age were prepared 
by TBI in a single fraction from dual opposed 6~  sources at an 
exposure rate of 20-25 cGy/min on the day before transplantation. 
Marrow obtained by femur flush was depleted of T lymphocytes 
by rabbit complement (1:10)-mediated lysis using a mixture of an- 
tibodies specific  for Thy-l.2 (30-H12, rat IgG2b; hybridoma kindly 
provided by Dr. J.A. Ledbetter, Bristol-Myers-Squibb,  Seattle, WA) 
(21), CD4 (GK1.5, rat IgG2b; hybridoma obtained from Amer- 
ican Type  Culture Collection [ATCC], Rockville, MD) (22), and 
CD8 (2.43, rat IgG2b; hybridoma obtained from ATCC) (23), each 
at optimal concentration. Nylon wool-nonadherent T lymphocytes 
from pooled mesenteric, axillary, and femoral lymph nodes were 
1 Abbreviation used in this ~per: TBI, total body irradiation. 
purified by centrifugal panning (24) on plastic petri dishes precoated 
with goat antibody against mouse Ig (10 #g/ml in pH 9.4 buffer, 
18 h at 4~  As determined by staining with FITC-conjugated 
hamster IgG mAb 145-2Cll (25) (hybridoma kindly provided by 
Dr. Jeffry Bluestone, University of Chicago, Chicago, IL), 97-99% 
of cells that did not adhere to the dishes expressed CD3. CD4- 
enriched T cells were isolated by centrifugal panning on dishes 
precoated with CD8-specific antibody 2.43, while CDS-enriched 
T cells were isolated by centrifugal panning on dishes precoated 
with CD4-specific antibody GK1.5. Staining with biotinylated an- 
tibodies and streptavidin-phycoerythrin  (SAPE) (Becton Dickinson 
& Co., Mountain View, CA) showed that the CD4-enriched popu- 
lations contained 92-96% CD4 cells and 0.7-1.0% CD8 cells, while 
the CDS-enriched populations contained 84-93%  CD8 cells and 
0.6-2.6% CD4 cells. T cell-depleted donor marrow (5.0  x  106 
cells/recipient) and purified T cells were injected into recipients 
via the lateral tail vein. 
Assessment of Chimerism.  Heparinized blood obtained from the 
orbital venous plexus was lysed with NH4C1 buffer. Leukocytes 
were stained with biotinylated H-2D  a (34-5-8S,  mouse IgG2a; 
hybridoma  obtained  from  ATCC) (26), H-2KkD  k (16-1-2N, 
mouse IgG2a; hybridoma obtained from ATCC) (27), Ly-5.1 (28) 
(A20-1.7, mouse IgG2a, hybridoma kindly provided by Dr. Shoji 
Kimura, Sloan Kettering Institute, New York, NY), or Ly-5.2 (28) 
(104-2.1, mouse IgG2a, hybridoma also provided by Dr.  Shoji 
Kimura) -specific  antibodies and SAPE (see reference  29 for nomen- 
clature of Ly-5 alleles). In some experiments, CD3-positive cells 
were stained for two-color analysis with FITC-conjugated antibody 
145-2Cll.  Stained cells were fixed in 1% paraformaldehyde and 
analyzed by flow cytometry using a FACScan  |  Becton Dickinson 
& Co.). Bit maps for lymphoid cells and granulocytes were deter- 
mined by forward and side scatter characteristics, and the percent 
of donor cells within each window was enumerated. Results were 
rounded to the nearest integer and were not corrected for back- 
ground staining. For each experiment, thresholds for delineating 
positive and negative  ceils  were determined by staining samples  from 
appropriate positive and negative controls. In the lymphoid and 
myeloid gates, respectively,  negative control samples showed 0-0.5 
and 0.4--4.9% background staining, while positive control samples 
showed 98-100 and 93-99%  stained cells. 
Results 
Effects  of TBI Exposure  and  Donor  T  Cells  on  Engraft- 
ment.  Initial experiments were carried out to determine the 
amount of TBI needed to allow engraftment of T cell-depleted 
marrow in MHC-disparate recipients. For this purpose, en- 
graftment of T  cell-depleted B6C3  marrow was tested in 
MHC  class  I  and  II,  and  minor  antigen-disparate  CB6 
recipients prepared with single-fraction TBI exposures ranging 
from 650 to 950 cGy in 50-cGy increments. Noteworthy in 
this experiment was the finding that all recipients survived 
for at least 35 d, regardless of the amount of  TBI or the number 
of T  cells  in  the graft.  On  day 32  after transplantation, 
chimerism of peripheral blood granulocytes was measured by 
staining with an H-2Da-specific antibody. In all recipients 
prepared with 950 cGy, at least 10%  of granulocytes were 
H-2D a negative and therefore originated from the donor 
(Table 1, Exp. 1). With exposures of 850-900 cGy, engraft- 
ment of donor cells could be detected in half of the recipients. 
None of the recipients prepared with 650-800 cGy had 910% 
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peat testing on day 95 after transplantation showed no de- 
tectable  engraftment  of donor  granulocytes  or T  cells in 
recipients prepared with 800 cGy TBI. Thus, with TBI ex- 
posures g800 cGy in this strain combination, rejection of 
the donor marrow occurred uniformly when the graft did 
not contain T  cells,  and recipients were reconstituted with 
hematopoietic cells of the host. 
Results were distinctly different when T cells isolated from 
lymph nodes of the donor were added to the T cell-depleted 
marrow.  With  2.5  x  105  donor  T  cells  added  to  the 
marrow, engraftment of donor granulocytes was observed in 
some recipients prepared with TBI exposures as low as 700 
cGy, and all recipients prepared with TBI exposures/>800 
cGy showed I>55% donor granulocytes on day 32 after trans- 
plantation (Table 1, Exp. 1). Retesting on day 95 after trans- 
plantation showed >--85% donor granulocytes and T cells in 
all recipients prepared with 800 cGy TBI. With  106 donor 
T cells added to the marrow, engraftment of donor granulo- 
cytes was observed on day 32 in four of five recipients pre- 
pared with 650 cGy, and all recipients prepared with ~>700 
cGy  showed  >--10% donor  granulocytes.  Most  of  these 
recipients had >50% donor granulocytes and all had >75% 
donor T  cells.  Thus,  the presence of donor T  cells in the 
marrow allowed engraftment when the amount of TBI would 
not otherwise have been sufficient to prevent rejection. 
A  similar experiment tested the effects of donor T  cells 
on engraftment of bml marrow in MHC class  I-disparate 
B6.Ly5  ~ recipients  prepared  with  single-fraction  TBI  ex- 
posures ranging from 700 to 900 cGy. On day 85 after trans- 
plantation, chimerism of peripheral blood granulocytes was 
determined by staining with an LyS.l-specific antibody. In 
the absence of donor T cells, rejections (<10% donor granu- 
locytes) occurred in some recipients prepared with TBI ex- 
Table  1,  Effects  of  Donor T Cells and TBI Exposure on Engraftment 
TBI  (cGy) 
No. of 
Exp.  T  cells  650  700  750  800  850  900  950 
1  None  0  0  0  0  2  3  5 
2.5  x  10  s  0  1  3  5  5  5  5 
1.0  x  106  4  5  5  5  5  5  5 
2  None  2  0  1  3  3* 
1.25  x  106  5  5  5  5  5 
Groups of five irradiated recipients were transplanted with 5.0  x  106 
T cell-depleted marrow cells with or without the indicated numbers of 
donor T cells added to the graft. Exp.  1 tested B6C3 donors and CB6 
recipients, while Exp.  2  tested bin1  donors  and  B6.LyS"  recipients. 
Chimerism was assessed by staining with H-2 class I (Exp.  1) or Ly5 
(Exp. 2) allele-specific antibodies. Data indicate the numbers of recipients 
in each group with 910%  donor granulocytes in the peripheral blood 
on day 32  (EXp. 1) or day 85  (Exp. 2) after transplantation. 
* One of the five recipients in this group died before day 85. 
posures as high as 900 cGy (Table 1, Exp. 2), and no T calls 
of donor origin were detected in any of the recipients pre- 
pared with  700 or 750 cGy TBI.  With  grafts containing 
1.25  x  106 donor T cells, engraftment (>110% donor gran- 
ulocytes) was observed in all recipients given TBI exposures 
as low as 700 cGy, and all recipients prepared with ~>750 cGy 
were reconstituted entirely with T cells of donor origin. Taken 
together, the results of these two experiments demonstrate 
that under certain circumstances, allogeneic marrow engraft- 
ment may require effects mediated by donor T  cells. 
Host T Cells Responsible  for Marrow Graft Rejection.  In CB6 
recipients, 800 cGy represented the highest TBI exposure uni- 
formly followed by rejection of T cell-depleted marrow from 
B6C3 donors.  The radioresistant host cells responsible for 
rejection in this model were identified by testing the effects 
of CD4-  or  CD8-specific  antibodies  administered  to  the 
recipients 5 d before transplantation. Control CB6 recipients 
transplanted with T cell-depleted B6C3 marrow without prior 
antibody administration uniformly rejected the grafts (Table 
2), consistent with results shown in Table 1. Recipients treated 
with CD4-specific antibody before transplantation also re- 
jected the grafts. In one experiment, donor cells persisted for 
;>67 d in some recipients treated with CD8-specific antibody 
(Table 2, Exp.  1).  In a second experiment, donor granulo- 
cytes (but not T cells) persisted for >45 d in some recipients 
treated with CD8-specific antibody, but these donor cells could 
not be detected on day 69 (Table 2, Exp. 2). In both experi- 
ments, donor cells persisted for ;>67 d in recipients treated 
with a mixture of CD4- and CD8-specific antibodies. These 
results suggested that either CD4 or CD8 cells of the host 
can mediate marrow graft rejection in this model. 
The ability of both CD4 and CD8 cells to mediate allogeneic 
marrow graft rejection was confirmed by tested the effects 
of host CB6 T cells added in graded numbers to grafts con- 
taining 5.0  x  104 T  cell-depleted donor B6C3 marrow cells 
transplanted into heavily irradiated (1,100 cGy) CB6 recipients. 
Controls transplanted with no host T cells added to the graft 
all  survived for >96  d  after  transplantation,  and all were 
durably engrafted with donor cells (Table 3). When as few 
as  5.0  x  104 CD4-  or  CD8-enriched  host  T  cells were 
added to the graft,  none of the recipients survived. With 
2.5  x  10  s CD4-enriched host T  cells added to the grafts, 
three deaths occurred 10 d after transplantation, and the re- 
maining two recipients died, respectively, on days 15 and 16. 
With  2.5  x  10  s CD8-enriched  host T  cells  added to the 
grafts, four deaths occurred, respectively, on days 15, 18, 22, 
and 22, and the remaining recipient died between 62 and 95 d 
after transplantation. Some recipients transplanted with grafts 
containing 2.0  x  103 or 1.0  x  104 CD4- or CD8-enriched 
host cells survived for >96 d after transplantation.  All four 
surviving recipients transplanted with grafts containing host 
CD4-enriched  T  cells were durably engrafted with donor 
cells. Three of the eight surviving recipients transplanted with 
grafts containing host CD8-enriched T cells had rejected the 
donor marrow and were reconstituted with host T ceils and 
granulocytes. When these rejections were taken into account 
together with the deaths before day 96,  the results of this 
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Percent  donor cells 
Antibody 
Exp.  Day  Treatment  T  cells  (mean)  Granulocytes  (mean) 
67  None  0,0,0,0,0  (0)  6,4,4,3,5  (4) 
CD4  0,0,0,0,0  (0)  7,2,1,2,4  (3) 
CD8  2,0,53,32  (22)  12,5,84,87  (47) 
CD4  +  CD8  46,7,28,35,100  (43)  68,23,15,76,92  (55) 
45  None  3,0,0,0,1  (1)  15,11,5,1,10  (8) 
CD4  0,0,0,0,0  (0)  1,2,2,4,2  (2) 
CD8  0,2,2,2  (2)  53,8,42,50  (38) 
CD4  +  CD8  45,54,3,5,4  (22)  88,88,68,78,72  (79) 
69  None  0,0,0,0,0  (0)  0,1,0,I,1  (1) 
CD4  0,0,0,0,0  (0)  1,0,2,1,0  (1) 
CD8  1,0,4,0  (1)  1,0,3,6  (3) 
CD4  +  CD8  70,67,37,28,15  (43)  95,92,89,58,15  (70) 
Groups of five CB6 recipients were injected intravenously with the indicated antibodies (50/zg each), exposed to 800 cGy TBI 5 d later, and trans- 
planted on the following day with 5.0  x  106 T cell-depleted B6C3 marrow cells. On the indicated days after transplantation, the percent donor 
T cells and granulocytes in the peripheral blood of survivors was determined by two-color staining with CD3 and H-2 class I allele-specific antibodies. 
Data indicate results for individual recipients. 
experiment  indicate that CD4- and CD8-enriched popula- 
tions had equivalent abilities  to mediate allogeneic marrow 
graft rejection. 
Donor  T  Cells  Responsible  for  Marrow  Graft  Enhance- 
ment.  The number of donor T  cells  required  to facilitate 
engraftment of B6C3 marrow in 800-cGy-irradiated MHC 
class I and II, and minor antigen-disparate CB6 recipient was 
determined in a titration experiment.  Controls transplanted 
with T  cdl-depleted marrow uniformly rejected the grafts 
(Table  4).  In four  of five recipients,  as  few  as  5.0  x  104 
Table  3.  Rejection Mediated by Host CD4 Cells and CD8 Cells 
Percent donor cells (day 96) 
Host T  Deaths before  Total 
cells added  day 96  T  cells  Granulocytes  rejections 
None  0  81,79,70,74,83  95,88,79,93,89  0 
2.0  x  103 CD4 +  2  90,80,88  81,43,89  2 
1.0  x  104 CD4 §  4  81  95  4 
5.0  x  104 CD4 +  5  5 
2.5  x  105 CD4 +  5  5 
2.0  x  103 CD8 +  1  81,85,1,77  89,78,1,85  2 
1.0  x  104 CD8 §  1  0,54,15,39  1,85,8,86  3 
5.0  x  104 CD8 §  5  5 
2.5  x  103 CD8 +  5  5 
Groups of five irradiated (1,100 cGy) CB6 recipients were transplanted with 5.0  x  10  e T cell-depleted B6C3 marrow cells with or without  the 
indicated numbers of host (CB6) T cells added to the graft. The CD4-enriched population used for this experiment contained 95% CD4 cells and 
1.5% CD8 cells, while the CD8-enriched population contained 87% CD8 cells and 2.4% CD4 cells. The percent donor T cells and granulocytes 
in the peripheral blood of recipients surviving on day 96 was determined by two-color staining with CD3 and H-2 class I allele-specific antibodies. 
Data indicate results for individual recipients. Recipients with <10% donor T calls or granulocytes on day 96 were considered as having rejected 
the marrow graft, One other experiment also showed that both CD4 and CD8 cells of the host could mediate allogeneic marrow graft rejection. 
706  Donor CD8 Calls Prevent Allogeneic Marrow Rejection in Mice Table  4.  Graft-enhancing  Effects of Donor T  Cells and T  Cell Subsets: Donor~Recipient Disparity  for MHC Class I and II Antigens 
and Minor Histocompatibility Antigens 
Percent  donor cells (day 39) 
Donor 
T  cells added  Lymphocytes  (mean)  Granulocytes  (mean) 
None  0,0,0,0,0  (0)  2,1,2,2,3  (2) 
0.5  x  10  s CD3 +  29,0,0,0,5  (7)  83,10,4,24,74  (39) 
2.5  x  10  s CD3 +  81,88,86,88,74  (83)  99,98,99,99,99  (99) 
12.5  x  10  s CD3*  70,66,89,79  (76)  99,100,99,97  (99) 
0.5  x  10  s CD8 §  96,99,99,99,99  (98)  97,96,94,98,99  (97) 
2.5  x  10  s CD8 §  88,90,24,81,67  (70)  99,99,83,99,96  (95) 
12.5  x  105 CD8 §  44,49,49  (47)  82,94,97  (91) 
0.5  x  105 CD4 §  0,0,0,0,0  (0)  2,1,2,9,1  (3) 
2.5  x  10  s CD4 +  0,0  (0)  2,2  (2) 
Groups of five irradiated (800 cGy) CB6 recipients were transplanted with 5.0  x  106 T cell-depleted B6C3 marrow cells with or without the indi- 
cated numbers of donor (B6C3)  T  cells added to the graft. On day 39 after transplantation, the percent donor lymphocytes and granulocytes in 
the peripheral blood of survivors was determined by staining with an H-2 class 1 allde-specific antibody. Data indicate results for individual recipients. 
One other experiment with B6C3 donors and CB6 recipients also showed that donor CD8 cells could facilitate allogeneic  marrow engraftment, 
while CD4 cells could not. 
donor T cells were sufficient to enable engraftment, but these 
recipients  remained mixed myeloid chimeras at 39 d after trans- 
plantation.  One of these recipients died on day 38, and the 
others subsequently rejected the grafts and were reconstituted 
with host T  calls and granulocytes. Full myeloid chimerism 
was seen on day 39 in all recipients when the grafts contained 
2.5  x  10  s or  1.25  x  106 donor T  cells.  Despite full my- 
eloid  chimerism,  host  lymphoid  cells  persisted  in  these 
recipients. 6 of the 10 recipients transplanted with grafts con- 
taining  2.5  x  10  s or 1.25  x  106 donor T  cells survived to 
117 d after transplantation,  and all were reconstituted with 
>95%  donor T  cells  and granulocytes. 
In the same experiment,  the effects of donor CD4- and 
CD8-enriched lymphoid subsets were tested by similar titra- 
tion. Full myeloid chimerism was seen in all recipients when 
the grafts contained as few as 5.0  x  104 CD8 cells.  Para- 
doxically, the extent of donor lymphoid chimerism appeared 
to decrease as the number of donor CD8 cells in the graft 
was increased. R.edpients transplanted with grafts containing 
5.0  x  104 donor CD8 cells were reconstituted entirely with 
donor T cells and granulocytes when retested on days 77 and 
117. Those transplanted with grafts containing larger numbers 
of donor CD8 cells all died by day 71. Donor CD4 cells caused 
severe GVHD and  early deaths  (see below). Three  of five 
recipients  transplanted  with  grafts  containing  2.5  x  10  s 
CD4 calls, and all five recipients transplanted with grafts con- 
taining  1.25  x  106 CD4 cells, died before day 39. None of 
the recipients  surviving after administration  of 5.0  x  104 
or 2.5  x  10  s donor T  cells  showed detectable numbers of 
donor  granulocytes  or lymphocytes.  Thus,  in  this  model, 
donor CD8 cells can facilitate allogendc marrow engraftment, 
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while donor CD4 cells administered in numbers that did not 
cause lethal  GVHD did not facilitate engraftment. 
Acute GVHD appeared to be more severe in recipients  trans- 
planted with CD4- or CD8-enriched T cells than in recipients 
transplanted with unseparated  CD3-positive T cells. Recipients 
transplanted  with  1.25  ￿  106 CD4-enriched  cells died be- 
tween 6 and 9 d after transplantation,  whereas the initial deaths 
in groups transplanted with 1.25  x  106 CD8-enriched cells 
or unseparated CD3-positive cells did not occur until days 
31 and 16, respectively. Recipients transplanted with 1.25  x 
106 CD8-enriched cells all died before day 50, whereas four 
of the five recipients transplanted with  1.25  ￿  106 unsepa- 
rated CD3-positive T cells survived beyond 50 d. Weight loss 
was somewhat greater in the group transplanted  with  5.0 
x  104 CD8-enriched  cells than  in the group transplanted 
with 5.0  ￿  104 unseparated CD3-positive T  cells (Fig.  1). 
Separate experiments showed that recipients  transplanted with 
1.25  ￿  106 CD4 cells had pulmonary vasculitis, acute nec- 
rotizing enteritis, and cellular marrows on day 6 after trans- 
plantation (pathologic review by Dr. Denny Liggitt, Univer- 
sity of Washington). Thus, GVHD rather than graft rejection 
was the likely cause of death in the experiments  described 
above. 
To address the question of whether donor CD4 cells could 
facilitate  engraftment under conditions where GVHD would 
not represent a limiting factor, engraftment of bml marrow 
was tested in B6.Ly5  ~ recipients prepared with 750-cGy TBI. 
In this strain  combination,  both rejection and GVHD are 
caused by MHC class I disparity. Controls transplanted with 
T cell-depleted marrow uniformly rejected the grafts (Table 
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Figure  1.  Severity  of GVHD caused by 0.5  x  105 (O), 2.5  x  105 (A), 
or 12.5  x  105 (El)  unseparated  CD3-positive  T  cells (A)  and CD8- 
enriched T cells (B). Controls (O) were transplanted with T cell-depleted 
marrow (5.0  x  105 cells) containing no added T cells. Results are taken 
from the same experiment described in Table 4. Numbers of mice sur- 
viving from groups originally containing five recipients are indicated in 
parentheses. Surviving recipients transplanted with marrow containing 
5  x  104 CD3-positive  T cells rejected the grafts between 39 and 77 d 
after transplantation,  while those transplanted with marrow containing 
5  x  104 CD8-enriched cells showed full donor chimerism when retested 
117 d after transplantation. 
T cells were sufficient to enable engraftment, and few, if any, 
host T ceils or granulocytes remained in these recipients when 
tested on days 34 and 64 after transplantation. When the ex- 
periment was terminated on day 86, there was no overt evi- 
dence of GVHD in the recipients transplanted with grafts 
containing 2.5  x  10  s CD8 cells. In contrast, rejection oc- 
curred by day 64 in four of five recipients transplanted with 
grafts containing 2.5  x  10  s CD4-enriched donor T cells and 
in two of five recipients  transplanted with 12.5  x  10  s CD4- 
enriched donor T cells. Results of this experiment indicate 
that the CDS-enriched population was at least fivefold more 
efficient than the CD4-enriched population for facilitating 
allogeneic marrow engraftment in this strain combination. 
Discussion 
This study was designed to explore the possible  mecha- 
nisms by which donor T lymphocytes can facilitate marrow 
engraftment in allogeneic recipients. In both strain combi- 
nations tested, it was possible to define conditions under which 
engraftment of aUogeneic marrow reproducibly depended on 
the presence of donor T  cells in the graft. As might have 
been expected, the amount of TBI represented a critical de- 
terminant of donor engraftment. Differences in sensitivity 
to irradiation were not strikingly apparent among the strain 
combinations tested, and single-fraction 6~  exposures in 
the range of 750-800 cGy delivered at '~20 cGy/min were 
sufficient for engraftment when donor T cells were present 
in the graft but not when they were absent. 
In both humans and in mice, an inverse relationship be- 
tween the amount of TBI exposure and the frequency of re- 
jection after T cell-depleted marrow transplantation has im- 
plicated an active role for host cells in causing rejections (3, 
18-20). In mice, rejection has been correlated with the number 
of clonable T cells remaining after TBI (30).  Furthermore, 
rejection can be prevented by administration of a CD3-specific 
antibody or immunotoxin before transplantation (31, 32). 
Table  5.  Graft-enhancing  Effects of Donor T  Cells and T  Cell Subsets: Donor~Recipient Disparity for MHC Class I Antigens 
Percent donor cells (day 64) 
Donor 
T  cells added  Lymphocytes  (mean)  Granulocytes  (mean) 
None  1,0,0,0  (0)  4,1,1,1  (2) 
0.5  x  105 CD8 +  0,0,0,0,0  (0)  2,1,1,1,1  (1) 
2.5  x  105 CD8 §  100,100,100,100,100  (100)  97,97,99,84,96  (95) 
0.5  x  10  s CD4 §  0,0,0,0,0  (0)  1,4,2,1,3  (2) 
2.5  x  105 CD4 +  67,0,0,0,0  (13)  82,5,2,1,1  (18) 
12.5  x  10  s CD4 +  48,50,44,0,0  (28)  78,81,47,2,1  (42) 
Groups of five irradiated  (750 cGy) B6.Ly5  a recipients were  transplanted  with 5.0  x  106 T cell-depleted bml marrow cells with or without the 
indicated numbers of donor (bml) T  cells added to the graft.  The CD8-enriched  population used for  this experiment  contained  88% CD8 cells 
and 0.6% CD4 cells, while the CD4-enriched population contained 95% CD4 cells and 0.7% CD8 cells. On day 64 after transplantation, the percent 
donor lymphocytes and granulocytes in the peripheral blood of survivors was determined by staining with an Ly5 allele-specific antibody. Data indi- 
cate results for individual recipients. 
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has come from observations demonstrating that T  ceils in 
irradiated mice can be sensitized by immunization with al- 
loantigen (33). A specific role for CD8 cells has been demon- 
strated by observations that rejection can be overcome by ad- 
ministration of CD8-specific antibody before transplantation 
(34) and that host CD8 T cell clones specific for MHC class 
I antigens of the donor can mediate rejection when coad- 
ministered with an allogeneic  marrow graft (35). 
Only limited evidence has previously suggested that host 
CD4 cells can mediate allogeneic marrow graft rejection in 
mice. In experiments similar to those described in this paper, 
it has been shown that allogeneic marrow engraftment in 
sublethally irradiated (600 cGy) mice can be facilitated by 
pretransplant administration of both CD4- and CD8-specific 
antibodies but not by either antibody alone (36). These results 
demonstrate that failure of donor engraftment after trans- 
plantation of T  cell-depleted marrow cannot be explained 
simply by competitive repopulation from radioresistant he- 
matopoietic stem cells of the host. Given the preponderance 
of evidence implicating CD8 ceils in causing rejection both 
in mice (34, 35) and in humans (11-17), we did not expect 
to find that CD4 and CD8 cells of CB6 mice have equivalent 
abilities to reject T cell-depleted B6C3 marrow. The CD4- 
enriched populations tested in our experiments contained 
>50-fold fewer CD8 ceils than the CD8-enriched popula- 
tion. Thus, small numbers of contaminating CD8 cells cannot 
explain the ability of the CD4-enfiched population to mediate 
marrow graft rejection. Given that pretreatment of recipients 
with both CD4- and CD8-specific antibodies could prevent 
rejection, it follows that rejection mediated by host CD4- 
and CD8-enriched populations cannot be explained by con- 
taminating cells that lack both markers.  Therefore, in this 
strain combination with disparity for MHC class I and II 
antigens as well as minor histocompatibility antigens, both 
CD4 and CD8 cells of the host can cause marrow graft rejec- 
tion, although rejections mediated by CD4 cells occurred ear- 
lier than those mediated by an equivalent number of CD8 cells. 
Several case reports have described the appearance of host 
CD8 cells with specific antidonor cytotoxic activity in pa- 
tients with graft failure after T cell-depleted marrow trans- 
plantation (11-17), but only a single case has been described 
where host CD4 cells with cytotoxic activity specific  for donor 
MHC class II antigens were detected shortly after rejection 
of a T cell-depleted marrow graft (37). Rejection mediated 
by CD4 cells might not have been observed ifCD4 cells have 
more sensitivity to irradiation than CD8 cells. Evidence has 
suggested, however,  that human CD4 cells and CD8 cells 
have equivalent radiation sensitivity as measured in T  cell 
cloning assays (38). An alternative explanation comes from 
observations that in vitro cytotoxic responses against MHC 
class II disparities  are diminished or preduded when T cells 
are stimulated simultaneously  by MHC class I and II dispari- 
ties as opposed to stimulation by class II disparity alone (39). 
The ability of CD4 cells to mediate marrow graft rejection 
does not necessarily imply that the most primitive hemato- 
poietic stem cells responsible for long-term reconstitution must 
express MHC dass II molecules. The expression of MHC 
class II antigens by more mature committed hematopoietic 
progenitors or by accessory cells necessary for hematopoiesis 
would allow effects functionally indistinguishable from re- 
jection of hematopoietic stem cells. 
Using short-term assays of hematopoiesis, Murphy et al. 
(40) showed that an absence of T  cells in murine marrow 
grafts leads to an increased susceptibility to rejection by host 
NK ceils and T cells. Rejection by either mechanism could 
be overcome by adding 20  x  106 donor thymocytes to the 
marrow grafts. Similarly, Lapidot et al. (41) showed that en- 
graftment of MHC-incompatible marrow could be facilitated 
by as few as 8  x  104 immunocompetent donor thymocytes. 
The present study showed that lymph node CD8 cells were 
much more effective than CD4 cells in facilitating durable 
engraftment of donor hematopoietic cells. While the experi- 
ment with bml donors and B6.Ly5a recipients suggested that 
CD4 cells may have limited graft-enhancing activity, it should 
be noted that the CD4-enriched population used for this ex- 
periment  contained 0.7%  CD8  ceils  and  *4%  double- 
negative (CD4-CD8-)  cells. Thus, the 12.5  x  l0  s CD4- 
enriched cells that enabled partial engraftment in three of 
five recipients contained *0.09  x  l0  s CD8 cells and 0.5  x 
105 double-negative cells. The 2.5  x  105 CDS-enriched cells 
that enabled full enlargement in all five recipients contained 
'~11%,  or  0.28  x  l0  s,  double-negative ceils. Although 
double-negative cells cannot explain the degree of graft facili- 
tation mediated by the CD8-enriched population, they could 
have contributed to the limited activity seen with the CD4- 
enriched population. Alternatively, subset interactions could 
have increased the activity of relatively small numbers of CD8 
ceils within the CD4-enriched population. 
Results from subset analysis in the present study may pro- 
vide important new insight into the mechanisms responsible 
for the marrow graft-enhancing effect mediated by donor 
T cells. Previous in vitro studies (42) have demonstrated that 
CD4 ceils can generate primary T  helper responses against 
MHC class II alloantigens and against MHC class I allodeter- 
minants presented by self-MHC class II molecules. CD4 ceils 
can also generate primary T cytotoxic responses against MHC 
class II alloantigens but not against MHC dass I alloantigens. 
CD8 cells can generate primary T  helper responses against 
MHC class I alloantigens and T cytotoxic responses against 
both MHC dass I and II alloantigens. Although CD8 cells 
mediate T cytotoxic responses against MHC class II antigens, 
this activity appears not to be sufficient for a graft-facilitating 
effect because CD4 ceils that also generate T  cytotoxic re- 
sponses against MHC class II antigens were relatively ineffec- 
tive for enhancing engraftment. Therefore, results of the 
present study implicate either T  helper or T  cytotoxic (or 
both) responses against MHC class I aUoantigens in the mech- 
anism(s) responsible for facilitation of allogeneic marrow en- 
graftment. The relative inability of CD4-derived T helpers 
to facilitate engraftment argues against the possibility that 
CD8-derived T helper responses are sufficient for allogeneic 
marrow graft facilitation unless it is postulated that this effect 
is mediated by a cytokine uniquely elaborated by CD8 cells. 
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class I alloantigens or class I-restricted peptides most likely 
represents the mechanism that accounts for much of the 
marrow graft-fadlitating effect of donor T cells. This activity 
may be mediated optimally by dual-function CD8 cells having 
both T  cytotoxic and T  helper responses  (43). 
The host CD4  and CD8 populations that contain the 
effectors responsible  for causing rejection are known to ex- 
press MHC class I antigens. Therefore, donor CD8 cells may 
facilitate engraftment simply by recognizing and eliminating 
the residual host T cells that survive the TBI administered 
before transplantation. The relative inability of donor CD4 
cells to facilitate engraftment in mice may be caused by the 
absence of MHC class II antigens on murine T lymphocytes 
(44). Although generation of donor cytotoxic T calls against 
host class I antigens may represent a highly potent mecha- 
nism for enhancement of allogeneic  marrow engraftment, 
mechanisms that do not depend on alloreactivity may also 
facilitate engraftment. For example, IL-2-activated donor cells 
can prevent rejection through veto inactivation of host T ceils 
(45). Alternatively,  T cells may elaborate cytokines that pro- 
mote engraftment. Lapidot et al.  (46) showed that mature 
CD8-positive thymocytes from donors genetically tolerant 
of host alloantigens could accelerate hematopoietic reconsti- 
tution during the first 2 wk after transplantation. Statisti- 
cally significant effects were observed with as few as 1.5  x 
106 CD8 cells, while similar numbers of CD4 cells had no 
effect. These experiments were carried out using recipients 
that had been treated with 8.0 Gy TBI and dimethylmyleran, 
a regimen that enables durable engraftment of T cell-depleted 
marrow in nonsensitized allogeneic recipients (47), unlike the 
pretransplant regimens used in our experiments. Thus, the 
experiments of Lapidot et al. (46) were not designed to de- 
termine whether donor CD8 cells tolerant of host alloan- 
tigens can prevent rejection, and this issue remains an open 
question. As shown in the present study, CD8 cells from 
nontolerant donors dearly do have this ability. 
Data from murine models cannot address whether CD4 
cells could facilitate engraftment more effectively in species 
whose T cells express MHC class II molecules after activa- 
tion, as is the case in humans (46). To some extent, this ques- 
tion has been addressed in clinical studies.  Champlin et al. 
(47) found that 4 of 36 patients (11%) transplanted with CD8- 
depleted HLA genotypically identical marrow and given cy- 
closporine after  transplantation had either failure of initial 
engraftment (n  =  3) or late graft failure (n  =  1). In their 
study, 28% of patients developed grades II-IV acute GVHD, 
suggesting that many donor/recipient pairs had disparity for 
minor histocompatibility antigens presented by MHC class 
II molecules. At least five immunologic explanations could 
have accounted for the graft failures: (a) the patients with 
graft failure may not have had disparity for minor histocom- 
patibility antigens that are presented by MHC class II mole- 
cules on activated  T  cells; (b) MHC class II molecules on 
human T  lymphocytes may not be able to present minor 
histocompatibility antigens; (c) donor CD4 cells might not 
mediate the effector functions necessary to facilitate engraft- 
ment through recognition of minor histocompatibility an- 
tigens presented by MHC class II molecules on activated host 
T cells; (d) cyclosporine might have interfered with the ability 
of donor CD4 cells to facilitate engraftment; or (e) graft failure 
might have been caused by a population of MHC class II-nega- 
tive host cells and not by T  lymphocytes. 
Data from our experiments demonstrate that under highly 
controlled conditions, it was possible to adjust the number 
and types ofT cells in the graft in a way that allowed reliable 
donor hematopoietic reconstitution in mice for at least 4 mo 
while minimizing the severity of acute GVHD. With B6C3 
donors and CB6 recipients,  the minimum number of CD3 
cells needed to produce durable engraftment (2.5  x  105) was 
also sufficient to cause GVHD that did not show improve- 
ment with time after transplantation.  The minimum number 
of CD8 cells needed to produce durable engraftment (5.0  x 
10 4)  also  caused  GVHD,  but  subsequent weight gain in 
these  recipients  suggested  that  GVHD  caused  by  small 
numbers of CD8 cells in this strain combination may be a 
self-limited process. Findings were similar in B6.LySa recipients 
transplanted with bin1 marrow containing 2.5  x  10  s donor 
CD8  cells. The  paradoxical  effect  of reduced  lymphoid 
chimerism in recipients transplanted with large numbers of 
donor CD8 cells could reflect an impairment of donor T cell 
development caused by GVHD-induced thymic atrophy. In 
humans with variable degrees of unmeasurable disparity for 
minor histocompatibility  antigens and with differences in the 
extent of pregnancy- and transfusion-induced alloimmuniza- 
tion of the donor and recipient, it seems unlikely that any 
given number of donor CD8 cells could enable engraftment 
without GVHD in all patients. Nonetheless, it might be pos- 
sible to adjust the number and types of donor T cells in the 
graft in ways that substantially reduce the risk of GVHD 
without increasing the risk of rejection. 
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